Edwards Lifesciences Corp
Latest Filing: May 6, 2026 • 25 Total Filings
Total Assets
2026
$13.32B
Total Revenue
2026
$1.65B
Net Income
2026
$380.70M
Operating Cash Flow
2026
$43.80M
Filing Year:
2025
Only 2025 data available
Data Source:
Showing data from all document types
Filters:
competes withcompetes with
Edwards Lifesciences Corp
Ticker: EW
Abbott Laboratories
Glucose monitoring devices, CGM systems
Major Competitor
Medtronic plc
Glucose monitoring devices, CGM systems, insulin pumps integrated with CGM
Major Competitor
Legend:
Company
Critical Supplier
Significant Supplier
Standard Supplier
Major Competitor
Emerging Competitor
Competitor